← Search & browse all drugs
ANTIINFECTIVES FOR SYSTEMIC USE › VACCINES › BACTERIAL AND VIRAL VACCINES, COMBINED › Bacterial and viral vaccines, combined
diphtheria-rubella-tetanus
J07CA03
Forms & Strengths
- Combined vaccine suspension for intramuscular injection
- Contains diphtheria toxoid, tetanus toxoid, and live attenuated rubella virus
- Single-dose and multi-dose vials or prefilled syringes (exact antigen concentrations vary by specific regional manufacturer)
Adult Dosing
- Not typically indicated for routine primary adult immunization
- 0.5 mL intramuscularly as a single booster dose if indicated for combined protection against diphtheria, tetanus, and rubella in specific public health scenarios
- Follow local immunization guidelines for booster intervals
Pediatric Dosing
- Not a standard primary childhood vaccine in most modern formularies (separate DTaP/DT and MMR are preferred)
- 0.5 mL intramuscularly administered according to catch-up schedules or specific regional public health protocols
- Preferred injection site is the anterolateral thigh in infants/young toddlers or the deltoid muscle in older children
Indications
- Active immunization against diphtheria, tetanus, and rubella
- Catch-up vaccination programs in specific epidemiological settings
Mechanism of Action
- Induces active immunity by stimulating the production of neutralizing antibodies against Corynebacterium diphtheriae toxin and Clostridium tetani toxin
- Induces humoral and cell-mediated immune responses against rubella virus to prevent congenital rubella syndrome and infection
Contraindications
- Severe allergic reaction (e.g., anaphylaxis) after a previous dose of any component or vaccine containing diphtheria, tetanus, or rubella
- Known hypersensitivity to any component of the vaccine, including neomycin, polymyxin, or gelatin (depending on specific formulation)
- Severe immunodeficiency (for the live attenuated rubella component)
Adverse Reactions
- Injection site reactions: pain, redness, swelling, and tenderness
- Systemic reactions: low-grade fever, irritability, malaise, headache, and myalgia
- Rare: anaphylaxis, generalized rash, lymphadenopathy (associated with rubella component)
- Very rare: hypotonic-hyporesponsive episode, brachial neuritis
Drug Interactions
- Immunosuppressive therapies (high-dose corticosteroids, chemotherapy, radiation) may reduce the immune response to the vaccine and increase risks from the live rubella component
- Immunoglobulins or blood products can interfere with the serological response to the rubella component and should be separated by several months
- Concomitant administration with other vaccines should be done using separate syringes and different injection sites
Curated Content: Needs Vetting Before Put to Clinical Use